Patents Represented by Attorney Eric J Sheets
-
Patent number: 5874165Abstract: The present invention is directed to support members having surfaces that are rendered hydrophilic for use as a substrate for the immobilization of bioactive species thereon. The hydrophilic surfaces are chemically stable on the support member. The surfaces are also chemically variable to provide a variety of chemically functional groups for immobilization of bioactive species thereto. The surfaces comprise polymeric surfactants attached onto the surfaces of a support member and covalently cross-linked thereon to form a first layer. Hydrophilic polymers are then attached to the first layer on the support member to form a second layer thereon. The second layer is used to enhance the hydrophilicity of a support member, as well as, to provide a substrate for immobilizing bioactive species thereto. Methods for forming the first and second layers are also provided. In addition, methods for attaching bioactive substances to the hydrophilic polymers are provided.Type: GrantFiled: May 27, 1997Date of Patent: February 23, 1999Assignee: Gore Enterprise Holdings, Inc.Inventor: Paul D. Drumheller
-
Patent number: 5846709Abstract: The present invention is directed to a method of amplifying and detecting single or double stranded target nucleic acid molecules. Amplification of the target nucleic acid molecule is accomplished by using at least two chemically modified oligonucleotide probes per target nucleic acid molecule to form a joined oligonucleotide product. Each oligonucleotide probe is comprised of a long and short sequence. The long sequence of each probe hybridizes to adjacent regions of the target nucleic acid molecule. The short sequences of each probe hybridize to each other. Chemical functionality groups attached to the short sequences of each oligonucleotide probe covalently combine linking the probes to form a joined oligonucleotide product. The joined oligonucleotide product is formed without the use of enzymes.The reactivity of the chemical functionality groups on each probe is target dependent.Type: GrantFiled: June 15, 1993Date of Patent: December 8, 1998Assignee: ImClone Systems IncorporatedInventor: David Segev
-
Patent number: 5843069Abstract: This invention relates generally to an implantable containment apparatus made of selectively permeable material. In particular, the implantable containment apparatus is used to contain a therapeutical device, such as a drug delivery device, a cell encapsulation device, or a gene therapy device. A therapeutical device can be easily placed and replaced in an apparatus of the present invention without damaging tissues associated with the selectively permeable material of the apparatus.Type: GrantFiled: July 10, 1997Date of Patent: December 1, 1998Assignee: Gore Hybrid Technologies, Inc.Inventors: Mark D. Butler, Daniel F. Davidson, Stanley L. Mish, James W. Moore, III
-
Patent number: 5787900Abstract: This invention relates generally to a method of loading and reloading a therapeutical device in a vascularized implantable containment apparatus made of selectively permeable material. Suitable therapeutical devices for use in the present invention include devices such as drug delivery devices, cell encapsulation devices, or gene therapy devices. A therapeutical device can be easily placed and replaced in a vascularized apparatus of the present invention without damaging tissues associated with the selectively permeable material of the apparatus.Type: GrantFiled: October 11, 1996Date of Patent: August 4, 1998Assignee: Gore Hybrid Technologies, Inc.Inventors: Mark D. Butler, Stanley L. Mish
-
Patent number: 5776182Abstract: This invention relates to improved vascular prostheses derived from mammalian blood vessels. The prostheses are fabricated from arterial segments from which the donor endothelium has been removed. A key aspect of this invention is the preservation of the subendothelial extracellular matrix that will serve as the blood interface of the vascular prostheses. The vessel segments are treated to reduce the likelihood of calcification and fixed with a tissue preservative. This invention results in vascular prostheses that are particularly useful for small diameter applications, such as arterial replacement requiring a diameter of 6 mm or less.Type: GrantFiled: December 2, 1996Date of Patent: July 7, 1998Assignee: W. L. Gore & Associates, Inc.Inventors: William Carl Bruchman, Anita Jean Switzer
-
Patent number: 5762600Abstract: This invention relates to improved vascular prostheses derived from mammalian blood vessels. The prostheses are fabricated from arterial segments from which the donor endothelium has been removed. A key aspect of this invention is the preservation of the subendothelial extracellular matrix that will serve as the blood interface of the vascular prostheses. The vessel segments are treated to reduce the likelihood of calcification and fixed with a tissue preservative. This invention results in vascular prostheses that are particularly useful for small diameter applications, such as arterial replacement requiring a diameter of 6 mm or less.Type: GrantFiled: June 18, 1996Date of Patent: June 9, 1998Assignee: W. L. Gore & Associates, Inc.Inventors: William Carl Bruchman, Anita Jean Switzer
-
Patent number: 5746856Abstract: A method of welding together overlapped edges of porous PTFE sheet materials by applying ultrasonic energy wherein the overlapped edges remain porous after welding. Composite articles made by the welding process are also described.Type: GrantFiled: April 24, 1996Date of Patent: May 5, 1998Assignee: W. L. Gore & Associates, Inc.Inventors: William J. Hendershot, Michael L. McDonald, Vivian J. Timian
-
Patent number: 5716394Abstract: This invention is directed to improved blood contact devices such as vascular prostheses rendered substantially nonthrombogenic through addition of a preserved layer of extracellular subendothelial matrix. The preserved subendothelial matrix layer, which serves as the blood interface of the device, is analogous to the subendothelial matrix layer beneath the endothelium of native vascular surfaces. The device consists of a permanent synthetic base material, preferably porous expanded polytetrafluoroethylene, on which this biologic layer of subendothelial matrix is grown in situ. The biologic layer is produced using in vitro tissue culture methods whereby living cells synthesize and deposit extracellular matrix components, after which the cells are killed and/or removed and the subendothelial matrix layer preserved before implantation. A key aspect of this invention is that no living Cells are present in the final configuration, so that the likelihood of recipient immunological response is minimized.Type: GrantFiled: April 19, 1995Date of Patent: February 10, 1998Assignee: W. L. Gore & Associates, Inc.Inventors: William Carl Bruchman, Paul Christopher Begovac
-
Patent number: 5626561Abstract: This invention relates generally to an implantable containment apparatus made of selectively permeable material. In particular, the implantable containment apparatus is used to contain a therapeutical device, such as a drug delivery device, a cell encapsulation device, or a gene therapy device. A therapeutical device can be easily placed and replaced in an apparatus of the present invention without damaging tissues associated with the selectively permeable material of the apparatus.Type: GrantFiled: June 7, 1995Date of Patent: May 6, 1997Assignee: Gore Hybrid Technologies, Inc.Inventors: Mark D. Butler, Stanley L. Mish
-
Patent number: 5584876Abstract: The present invention is directed to a sheath for use with vascular prostheses derived from donor blood vessels, particularly mammalian blood vessels. A vascular prosthesis of the present invention employs an external sheath around a donor blood vessel. The sheath prevents access to the donor vessel wall by host cells originating from perigraft tissue. While resistant to host cell ingrowth, the external sheath is permeable to the flux of macromolecules across its thickness. The exclusion of host cells by the external sheath and the bi-directional flow of macromolecules through the external sheath assists in maintaining the original function of the underlying donor vascular tissue of the prosthesis.Type: GrantFiled: April 29, 1994Date of Patent: December 17, 1996Assignee: W. L. Gore & Associates, Inc.Inventors: William C. Bruchman, Anita J. Switzer
-
Patent number: 5437977Abstract: A method for amplifying a signal during the detection of target nucleic acid molecules utilizes a primary oligonucleotide probe that binds to a bridging nucleic acid molecule. The bridging molecule hybridizes to a first developer nucleic acid molecule. Each first developer molecule comprises: (a) a first branch having a sequence of at least two different nucleotides and at least six total nucleotides complementary to a sequence of a first branch of a second developer molecule; (b) a second branch comprising a sequence of at least two different nucleotides and at least six total nucleotides complementary to a sequence of a second branch of the second developer molecule; and (c) a detectable label.Type: GrantFiled: May 29, 1992Date of Patent: August 1, 1995Assignee: David SegevInventor: David Segev
-
Patent number: 5367057Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1 (murine flk-2), FIG. 2 (human flk-2) and FIG. 3 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1 (murine flk-2); FIG. 2 (human flk-2) and FIG. 3; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: April 30, 1993Date of Patent: November 22, 1994Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 5338833Abstract: This invention relates to a Carboxy Terminal IL-6 Mutein with enhanced biological activity. The invention comprises a mutein of IL-6 having increased activity wherein the mutein has an amino acid substitution at, or corresponding to, amino acid location 171 or 175 of IL-6 having the wild-type sequence.Type: GrantFiled: July 23, 1992Date of Patent: August 16, 1994Assignee: The University of North Carolina at Chapel HillInventor: Dana M. Fowlkes
-
Patent number: 5334532Abstract: The present invention provides a method for production of recombinant PDGF-B in prokaryotic cells. Also provided are DNA constructs for fusion protein useful in the production of the biologically active product.Type: GrantFiled: June 4, 1991Date of Patent: August 2, 1994Assignee: ImClone Systems IncorporatedInventors: Charles Tackney, Jurgen Hoppe, Wolfram Eichner, Herbert Weich
-
Patent number: 5283354Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: September 17, 1992Date of Patent: February 1, 1994Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 5270458Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: November 19, 1992Date of Patent: December 14, 1993Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 5248781Abstract: Substituted anilino-nicotinic acid derivatives are readily prepared from the condensation of two intermediates, 2-alkyl-3-perfluoroalkyl-anilines and alkyl 2-chloronicotinates. The 2-alkyl-3-perfluoroalkyl-aniline intermediate can be prepared via a novel three step synthesis. 3-Perfluoroalkyl-anilines are reacted with an amine directing protecting group reagent to protect the amine. The protected amine is then alkylated, and finally, the directing group is removed to form the 2-alkyl-3-perfluoroalkyl-aniline intermediate. The 2-alkyl-3-perfluoroalkyl-aniline intermediate is condensed with the alkyl 2-chloronicotinate to form the anilino-nicotinic acid derivative.Type: GrantFiled: September 21, 1992Date of Patent: September 28, 1993Assignee: The Trustees of Princeton UniversityInventor: Alexander McKillop
-
Patent number: 5185438Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1 (flk-2) and FIG. 2 (flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1 (flk-2) and FIG. 2 (flk-1); ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: December 24, 1991Date of Patent: February 9, 1993Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka